Articles tagged with Cancer Immunotherapy
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
The phase III PATINA study demonstrated that adding CDK4/6 inhibitor palbociclib to standard maintenance therapy significantly prolongs progression-free survival by more than 15 months compared to standard therapy alone. The study found a meaningful improvement in median PFS with no new signals.
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
A new Phase II trial will examine whether giving chemotherapy or chemotherapy combined with immunotherapy before surgery can improve survival compared to surgery alone. The trial aims to identify a treatment that will help patients live longer without the cancer returning.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
Scientists have developed a novel immunotherapy approach that targets tumor macrophages, converting them from immune suppressors to killers. The therapy, using engineered CAR T cells, has shown promising results in preclinical models of metastatic ovarian and lung cancer.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
Researchers at Umea University have discovered a bacterial toxin, MakA, that can inhibit colorectal cancer growth without causing damage to the body. The substance changes the immune microenvironment in tumors and boosts the immune system's ability to fight cancer.
A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.
Researchers have developed a new way to boost the immune system's response to cancer by using specially engineered antibodies. The antibodies work by clustering multiple immune cell receptors, amplifying the signal that tells T cells to attack cancer cells.
Researchers develop CAR T cell therapy that recognizes BCMA and BAFF-R proteins, providing a new approach to treating multiple myeloma. The treatment has shown promise in preclinical trials, with the potential to prevent relapse and extend lifespan.
The collaboration aims to address bottlenecks in solid tumor manufacturing and accelerate advancement into clinical trials. City of Hope's investigational gene-modified CAR T cell therapy targeting glioblastoma will be evaluated using Cellares' automated manufacturing platform and quality control system.
A new study reveals that Cornell prime dots, ultrasmall fluorescent particles, can reprogram the tumor microenvironment to make it more responsive to treatment. The nanoparticles induce anti-tumor effects by stimulating innate immune responses and reprogramming key immune cells.
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers from MIT and Broad Institute develop temporary 'factory' in the liver to generate T-cell-stimulating signals, boosting immune response to vaccination and cancer immunotherapy treatments. Aged mice showed significant increases in T cell population size and function after treatment.
Researchers at EPFL have developed two bioengineering approaches that exploit extracellular vesicles to train dendritic cells to identify cancer cells without the need for tumor material. The approaches, published in Nature Communications and Science Translational Medicine, show promising results in enhancing cancer immunotherapy.
Researchers developed a new way to stimulate the immune system to attack tumor cells by blocking an immune checkpoint. They created multifunctional molecules called AbLecs, which combine a lectin with a tumor-targeting antibody, and showed they could boost the immune response to cancer cells.
A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.
The study found that the investigational vaccine produced an immune response in 74% of participants and was safe and well-tolerated. A Phase 2 study is planned to evaluate the vaccine's efficacy, offering new hope for triple-negative breast cancer treatment.
Researchers at USC's Keck School of Medicine have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer. The engineered CAR T cells may offer a way to more safely treat blood cancers and reduce the chance of relapse.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
Researchers found that CAR T cell therapy side effects, such as neurotoxicity and intestinal inflammation, are linked to high rates of death unrelated to cancer relapse. CirAEs were more common in patients who received cilta-cel and had higher non-relapse mortality rates.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
Researchers have discovered that rhesus macaques shed TIGIT from immune cell surfaces when exposed to plasmin, a natural enzyme involved in blood clot breakdown. This creates a soluble form of TIGIT that can still bind anti-TIGIT monoclonal antibodies, potentially leading to misleading safety and efficacy data for human trials.
A new study found that patients with advanced basal cell carcinoma may benefit from receiving immunotherapy earlier, with a significant increase in objective response rate. Researchers explored adding relatlimab to nivolumab and saw promising results in overcoming resistance to single-agent anti-PD-1.
Researchers developed an RNA-based therapeutic strategy targeting mutant KRAS genes, stimulating the immune system to attack tumours. The treatment, combining antisense oligonucleotides and immunomodulatory RNA, effectively killed cancer cells in laboratory studies, reducing tumour burden and extending survival.
A new biomimetic mRNA delivery platform improves PTEN expression levels in patients with colorectal cancer. The system boosts precision immunotherapy by targeting tumors and evading the immune system.
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
A recent review in the Chinese Medical Journal uncovers how circulating tumor cells evade immune elimination, highlighting their interactions with immune cells and blood components. The study suggests new therapeutic targets, including anti-platelet therapy and immune checkpoint inhibitors, to combat cancer metastasis.
The American Society for Radiation Oncology (ASTRO) has announced three winning research proposals for the 2025 ASTRO-AstraZeneca Small Cell Lung Cancer Therapy Challenge. The selected projects aim to improve therapies and outcomes for patients with limited-stage SCLC through immunotherapy and radiation techniques.
Researchers developed nanomachines that can function stably within living organisms, enabling starvation therapy to treat refractory pancreatic cancer. This approach improved treatment outcomes by depleting essential nutrients for cancer cell growth.
Researchers at Mass General Brigham have developed a strategy to promote antitumor immunity by inducing cancer cells to produce an immune-activating molecule. This approach was shown to reduce tumor growth and improve survival in mouse models of aggressive melanoma, with potential applications beyond cancer therapies.
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
Researchers at Monash University have developed a new strategy to improve CAR T cell therapy for solid tumors. By targeting the PTPN2 protein, they enhanced the efficacy of CAR T cells and generated long-lived memory T cells that can persist in circulation.
A UCLA study finds that DNA copy-number changes enable melanoma cells to resist immune attacks, leading to tumor relapse. The researchers suggest a strategy to make tumors more prone to self-destruction after immune attacks, potentially extending the effectiveness of immunotherapy.
The Innovative Cancer Medicines (ICM) initiative, a collaboration between CHAI and PICI, has enrolled the first Nigerian patient in a demonstration project using an immunotherapy drug. The goal is to develop sustainable and effective administration of innovative immuno-oncology therapies in low- and middle-income countries.
The review highlights how T cells specifically recognize and eliminate malignant cells through antigen recognition mechanisms. It also explores how tumors evade immune surveillance through various mechanisms and discusses potential therapeutic strategies, including combination therapies to improve response rates for cancer patients.
A new blood-based liquid biopsy model, LiBIO score, predicts immunotherapy response with high accuracy. The model identifies an early post-treatment time point as optimal for assessing treatment response and can help identify patients who are more likely to benefit from immunotherapy.
UofL Health – Brown Cancer Center oncologists and researchers will continue developing novel therapies using patients' own immune system to defeat cancer. The center's faculty and research facilities support clinical trials that bring new treatments to patients.
Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.
Researchers at NYU Langone Health found that pembrolizumab therapy results in a trend toward improvement in survival rates for patients with Merkel cell carcinoma. After two years, 73% of patients taking pembrolizumab showed no signs of cancer recurrence.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A new class of anti-cancer agents—antibody-drug conjugates (ADCs)—has unveiled compelling evidence that can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer. The phase III DESTINY-Breast05 and DESTINY-Breast11 trials have shown superior efficacy and improved disease-free survival rates, positionin...
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
A study found that higher thymic health is associated with better outcomes in cancer patients treated with immunotherapy, including a 35% lower risk of cancer progression and 44% lower risk of death. Thymic health may serve as a non-invasive biomarker of adaptive immune competence in various cancers.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
A new mRNA cancer vaccine platform has been developed using a hydrogel-based approach that actively recruits immune cells. This improves efficiency and leads to stronger antitumor immune responses in preclinical models. The research is still in its early stages, but it holds promise for future cancer treatments.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
A new method has been developed to generate induced natural killer cells and CAR-engineered NK cells from cord blood-derived hematopoietic stem and progenitor cells. This approach increases the induction efficiency of NK cells and lowers the cost of CAR engineering, offering a promising avenue for cancer immunotherapy.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.